SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-197822
Filing Date
2023-07-28
Accepted
2023-07-28 17:19:33
Documents
17
Period of Report
2023-07-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d533315d8k.htm   iXBRL 8-K 35641
2 EX-1.1 d533315dex11.htm EX-1.1 220755
3 EX-5.1 d533315dex51.htm EX-5.1 7422
4 EX-99.1 d533315dex991.htm EX-99.1 9801
8 GRAPHIC g533315g0728202305786.jpg GRAPHIC 3470
9 GRAPHIC g533315g0728202456631.jpg GRAPHIC 2240
  Complete submission text file 0001193125-23-197822.txt   476620

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA inzy-20230727.xsd EX-101.SCH 2851
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE inzy-20230727_lab.xml EX-101.LAB 18738
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inzy-20230727_pre.xml EX-101.PRE 11708
11 EXTRACTED XBRL INSTANCE DOCUMENT d533315d8k_htm.xml XML 3463
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39397 | Film No.: 231124201
SIC: 2834 Pharmaceutical Preparations